Spots Global Cancer Trial Database for Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)

Official Title: Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)

Study ID: NCT04780854

Conditions

Chemotherapy-induced Peripheral Neuropathy

Interventions

Metformin

Placebo

Study Description

Brief Summary: Chemotherapy cause many adverse events including induction of peripheral neuropathy. Metformin, the AMPK activator, was found to have protective effect against chemotherapy induced peripheral neuropathy in mouse model and in clinical trials as well. There are different hypothesized mechanisms through which metformin does the protective effect. Such as enhancing mitochondrial activity, reduction of ROS and nitric oxide and activation of AMPK.

Detailed Description: Chemotherapy can cause a variety of side effects. One of the most common side effects is Chemotherapy induced peripheral neuropathy (CIPN), it commonly caused by Paclitaxel chemotherapy which is usually used in the treatment of breast cancer. Metformin which is known as a safe anti-diabetic drug, was found to have a protective effect on neurons. It gave positive results in chemotherapy induced peripheral neuropathy in mouse models and in some clinical trials